E20210210Recruiting

Safety and Efficacy of a Synthetic Mesh in Two-Stage Surgical Breast Reconstruction

Gender
Women
Age
18–70 years
Trial type
Interventional
Line of therapy
First line
Phase

What is this trial about?

The standard treatment for early-stage breast tumors typically involves breast-conserving surgery followed by radiation therapy. After breast-conserving or skin-sparing breast surgery, a patient may choose to undergo breast reconstruction. The goal of this study is to evaluate the effectiveness and safety of a special plastic mesh (TiLOOP® Bra Mesh) in two-stage breast reconstruction. Women between the ages of 18 and 70 who do not have cancer cells that have spread to other organs (metastases) and who are in good health are eligible to participate.

Trial flow

Requirements

Diagnosis: Breast cancer

Age: 18–70 years

Line of therapy: Erstlinie / bisher keine Therapie

Key inclusion criteria: Women; no distant metastasis; BMI < 35 kg/m2

Allocation

Randomisierung

Treatment

Breast reconstruction with breast mesh
Breast reconstruction without breast mesh

Follow-up

60 months

Detailed description

Breast cancer (mammary carcinoma) is the most common cancer among women worldwide. After breast surgery to remove the tumor (mastectomy), patients often wish to have breast reconstruction. This reconstruction is usually performed in two stages: First, a tissue expander is inserted and gradually filled with fluid to stretch the skin. The expander is then replaced with a permanent implant. Complications can arise during this process, such as capsular contracture (a painful hardening around the implant) or infections. The use of a special plastic mesh (TiLOOP® Bra Mesh) could potentially improve treatment outcomes in this context. The mesh is intended to provide better support for the expander, facilitate stretching, and improve the aesthetic outcome.

The aim of this study is to examine whether the use of TiLOOP® Bra Mesh offers advantages over standard therapy and whether complications associated with breast reconstruction can be reduced. The study is randomized, controlled, and blinded, meaning that patients are randomly assigned to one of two groups. In one group, breast reconstruction is performed using TiLOOP® Bra Mesh; in the other, it is performed without this mesh. Neither the patients nor the physicians evaluating the results know which method was used. The study primarily examines the complication rate (e.g., infections, implant displacement, capsular contracture) as well as the efficiency of tissue expansion. In addition, the aesthetic outcomes, patient satisfaction, psychological effects, and potential follow-up costs will be analyzed.

Eligible participants are women between the ages of 18 and 70 with newly diagnosed breast cancer without metastases who opt for a skin- or nipple-sparing mastectomy followed by reconstruction. They must be physically fit (Karnofsky Index > 80) and must not have any serious comorbidities. A body mass index (BMI) over 35 kg/m², previous radiation therapy to the breast, advanced or inflammatory breast cancer, pregnancy, breastfeeding, severe allergies, alcohol or drug abuse, and severe mental health disorders exclude participation.

Facts

  1. What disease: Breast cancer (breast carcinoma)
  2. Cancer characteristics: Women without distant metastases, no prior radiation therapy, good general health, following mastectomy
  3. What the study investigates: Breast reconstruction with or without a synthetic mesh
  4. Study objective: To reduce complications and achieve better cosmetic outcomes through the use of synthetic mesh
  5. Study duration: Up to 5 years total, with follow-up for up to 24 months after surgery
  6. Study characteristics: two groups, randomized, controlled, triple-blind, approximately 300 participants

Trial sites

1 trial site in Germany is listed.

  • Technische Universität München

    Munich

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT04967976) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.